Opinion

Vertex is buying Crinetics for $10 billion. Here's what investors need to know.

The drugmaker is paying up for a new growth engine. Is the price disciplined?
BioPharma Dive

Vertex was sole bidder in high-premium Crinetics acquisition

Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click for more on VRTZX and CRNX stock.

Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug ...

Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse

Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for ...

Vertex Pharmaceuticals to acquire Crinetics Pharmaceuticals for $10 billion

The acquisition would add to Vertex’s pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.
Investopedia

Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch

Deal Values Each Alpine Share at a 38% Premium to Wednesday’s Closing Price Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Vertex shares ...